28 May 2013, London: College Hill Life Sciences congratulates all the nominees shortlisted for the European Mediscience Awards 2013, especially those individuals and companies in the category, Commentator of the Year, of which College Hill is the sponsor.
Of College Hill Life Sciences own clients, congratulations go to Clinigen Group (Transaction of the year, Emerging Company), Imperial Innovations (Most Significant Contribution), and Oxford Gene Technology (Emerging Star). The full list of nominees can be found here: www.mediscience-event.co.uk/shortlist and represents a broad cross-section of companies and individuals who have made significant difference to the sector from 1 April 2012 to 31 March 2013. Good luck to all nominees.
College Hill has been a sponsor of the European Mediscience Awards for five years, this year sponsoring the award for "Mediscience commentator of the year" which recognises the importance of clear and concise commentary on the sector. The criteria for the award are for an analyst, a journalist, a columnist, a research house, a specialist website or a team that is dedicated to providing sharp, perceptive and penetrating commentary about the sector. In-depth knowledge of the sector is a given; the Voting Panel looks for excellence in the way that knowledge is communicated to the wider audience. Previous winners include the teams at BioCentury and EP Vantage, and this year’s shortlisted nominees are Julie Simmonds (Canaccord Genuity), the team at Kempen & Co, Daniel Mahoney (Polar Capital), the team at SCRIP and Andrew Clark (the Times).
Commenting on the announcement of the shortlisted nominees, Melanie Toyne Sewell, Partner, Life Sciences and a member of the voting panel said:
"Congratulations to all shortlisted nominees of the European Mediscience Awards 2013. The breadth of the nominees selected by the voting panel is the largest for some years, and demonstrates the strength of the Mediscience sector, even in difficult economic times. The selection of nominees was especially difficult this year, due to the increase in activity in the sector – not only in the size and quality of transactions being done but also in the clinical advances being made across the board. We very much look forward to Awards dinner on 20 June 2013 and the announcement of the winners. Good luck to all."
College Hill is a leading international business communications consultancy with an exceptionally strong focus in the Mediscience sector. Its Life Sciences team is unique in that it has expertise across financial, corporate, healthcare and marketing communications, and integrates design into its communications mix. College Hill Life Sciences also offers seamless global outreach with teams located in the UK, Germany, Australia and the US. Its client base spans pharma, biotechnology, medical devices, diagnostics, healthcare, laboratory supply and service providers in addition to venture capitalists, recruitment companies, not-for-profit, academic organisations and science-associated bodies.
For Further Information:
Managing Partner, Life Sciences
+44 (0)20 7457 2020
Melanie Toyne Sewell
Partner, Life Sciences
+44 (0)20 7457 2020
European Mediscience Awards
Ford Sinclair Events
+44 (0)1277 350 557
Jo Thomas / Christine Restall
jo[at]ford-sinclair.co.uk / chris[at]ford-sinclair.co.uk
About the European Mediscience Awards Dinner
The European Mediscience Awards celebrates the best in the quoted life science, healthcare and biotech industries. It is the premier networking event for all stakeholders working in or with quoted mediscience companies in Europe and has over 500 attendees. Nominations for the awards can be made online from the beginning of April via the event website www.mediscience-event.co.uk where the criteria for each award and a full list of eligible companies can also be viewed. To be eligible for an award, the majority of the business of the company, and its subsidiaries, must be in the healthcare (animal and human), medical, pharmaceutical, biotechnology or life sciences sectors. In addition, a significant part of the company's, and its subsidiaries', activities should involve scientific research and development which may or may not be product specific.